GlassScriptPhysician profile
Matthew Warren Hurley
NPI 1821362088
$1,400.99
in general payments reported to CMS, 2019-2025
19 companies · $159 in 2025
The $159 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.03 · 2020: $26.37 · 2021: $15.64 · 2022: $67.82 · 2023: $543 · 2024: $551 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $291.70 | 2023-2025 | |
| Abbvie INC. | $268.62 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $98.67 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $95.86 | 2023-2024 | Breztri, Airsupra |
| Abbott Laboratories | $95.59 | 2023-2024 | Freestyle Libre |
| Exact Sciences Corporation | $89.54 | 2023-2024 | Cologuard Collection Kit |
| Harmony Biosciences LLC | $83.12 | 2024 | |
| Novo Nordisk INC | $75.27 | 2023-2024 | Ozempic, Rybelsus |
| Amgen INC. | $55.82 | 2019-2024 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $48.86 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Valinor Pharma, LLC | $46.14 | 2024 | Movantik |
| Allergan, INC. | $26.37 | 2020 | |
| Dexcom, INC. | $23.65 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $21.94 | 2023 | Rexulti |
| Lilly USA, LLC | $17.78 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.40 | 2024 | |
| Apria Healthcare LLC | $15.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.79 | 2023 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hurley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.